Insulet Co. (NASDAQ:PODD) Position Raised by Diversify Wealth Management LLC

Diversify Wealth Management LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 51.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,762 shares of the medical instruments supplier’s stock after acquiring an additional 935 shares during the period. Diversify Wealth Management LLC’s holdings in Insulet were worth $751,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of PODD. Arkadios Wealth Advisors lifted its holdings in shares of Insulet by 59.9% in the fourth quarter. Arkadios Wealth Advisors now owns 2,056 shares of the medical instruments supplier’s stock valued at $537,000 after buying an additional 770 shares during the period. Sax Wealth Advisors LLC lifted its holdings in Insulet by 101.3% in the 4th quarter. Sax Wealth Advisors LLC now owns 3,044 shares of the medical instruments supplier’s stock valued at $795,000 after acquiring an additional 1,532 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Insulet during the 4th quarter valued at about $1,760,000. Contravisory Investment Management Inc. acquired a new position in shares of Insulet in the 4th quarter worth approximately $552,000. Finally, USA Financial Formulas bought a new stake in shares of Insulet in the 4th quarter worth approximately $1,234,000.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $276.08 on Wednesday. Insulet Co. has a one year low of $160.19 and a one year high of $282.86. The business’s 50-day moving average price is $266.32 and its two-hundred day moving average price is $234.07. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $19.36 billion, a P/E ratio of 47.27, a price-to-earnings-growth ratio of 3.46 and a beta of 1.22.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the prior year, the company posted $0.71 earnings per share. Analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.47% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PODD. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Wells Fargo & Company lifted their target price on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Citigroup upped their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Morgan Stanley boosted their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.